IL274844A - Il-2 muteins and uses thereof - Google Patents
Il-2 muteins and uses thereofInfo
- Publication number
- IL274844A IL274844A IL274844A IL27484420A IL274844A IL 274844 A IL274844 A IL 274844A IL 274844 A IL274844 A IL 274844A IL 27484420 A IL27484420 A IL 27484420A IL 274844 A IL274844 A IL 274844A
- Authority
- IL
- Israel
- Prior art keywords
- muteins
- Prior art date
Links
- 101150083678 IL2 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595357P | 2017-12-06 | 2017-12-06 | |
| US201862675972P | 2018-05-24 | 2018-05-24 | |
| US201862721644P | 2018-08-23 | 2018-08-23 | |
| US16/109,875 US10174091B1 (en) | 2017-12-06 | 2018-08-23 | IL-2 muteins |
| US16/109,897 US10174092B1 (en) | 2017-12-06 | 2018-08-23 | IL-2 muteins |
| PCT/US2018/062808 WO2019112854A1 (en) | 2017-12-06 | 2018-11-28 | Il-2 muteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL274844A true IL274844A (en) | 2020-07-30 |
Family
ID=66751187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274844A IL274844A (en) | 2017-12-06 | 2020-05-21 | Il-2 muteins and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3720470A4 (en) |
| JP (1) | JP7250790B2 (en) |
| KR (3) | KR102687035B1 (en) |
| CN (2) | CN118515780A (en) |
| AU (2) | AU2018378078B2 (en) |
| BR (1) | BR112020011343A2 (en) |
| CA (1) | CA3083941A1 (en) |
| IL (1) | IL274844A (en) |
| MX (1) | MX2020005208A (en) |
| SG (1) | SG11202003965VA (en) |
| WO (1) | WO2019112854A1 (en) |
| ZA (1) | ZA202003386B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNTOLERANCE |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3720871A4 (en) * | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | TARGETED IMMUNTOLERANCE |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| TW202110885A (en) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | Madcam targeted immunotolerance |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| CN114728179A (en) * | 2019-08-19 | 2022-07-08 | 潘迪恩运营公司 | Targeted immune tolerance with PD-1 agonists |
| CN110642934B (en) * | 2019-09-10 | 2022-08-23 | 中国医学科学院北京协和医院 | Long-acting interleukin-2 of target regulatory T cell and application thereof in treating autoimmune disease |
| WO2021076805A1 (en) | 2019-10-15 | 2021-04-22 | Moderna TX, Inc. | Mrnas encoding immune modulating polypeptides and uses thereof |
| TW202136317A (en) | 2019-12-20 | 2021-10-01 | 美商再生元醫藥公司 | Novel il2 agonists and methods of use thereof |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| CN112358540A (en) * | 2020-11-03 | 2021-02-12 | 安徽环球基因科技有限公司 | Production method of recombinant IL2 in pichia pastoris |
| MX2023006599A (en) | 2020-12-04 | 2023-06-19 | Visterra Inc | Methods of using interleukin-2 agents. |
| TW202317623A (en) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | Il2-based therapeutics and methods of use thereof |
| TWI859752B (en) * | 2022-03-03 | 2024-10-21 | 大陸商海南先聲藥業有限公司 | Pharmaceutical compositions of il2 mutant-antibody fc segment fusion proteins and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1007907B (en) * | 1985-04-30 | 1990-05-09 | 弗·哈夫曼-拉罗彻有限公司 | Purification of Recombinant Human Interleukin-2 |
| WO2005007121A2 (en) * | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| JP6093712B2 (en) * | 2010-12-22 | 2017-03-08 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Interleukin 2 superagonist and antagonist |
| US20140170153A1 (en) * | 2011-05-31 | 2014-06-19 | Novo Nordisk A/S | Il-21 epitope and il-21 ligands |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| MX378790B (en) * | 2014-07-21 | 2025-03-10 | Delinia Inc | MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES. |
| CN109071623B (en) * | 2016-05-04 | 2022-05-27 | 美国安进公司 | Interleukin-2 muteins for expansion of T regulatory cells |
| EP3606947B1 (en) * | 2017-04-03 | 2022-12-21 | F. Hoffmann-La Roche AG | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
| AU2018273914A1 (en) * | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| EP3720871A4 (en) * | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | TARGETED IMMUNTOLERANCE |
| US20220041713A1 (en) * | 2018-09-18 | 2022-02-10 | Pandion Operations, Inc | Targeted immunotolerance |
-
2018
- 2018-11-28 BR BR112020011343-3A patent/BR112020011343A2/en unknown
- 2018-11-28 JP JP2020530653A patent/JP7250790B2/en active Active
- 2018-11-28 CN CN202410591221.4A patent/CN118515780A/en active Pending
- 2018-11-28 MX MX2020005208A patent/MX2020005208A/en unknown
- 2018-11-28 EP EP18887098.4A patent/EP3720470A4/en active Pending
- 2018-11-28 WO PCT/US2018/062808 patent/WO2019112854A1/en not_active Ceased
- 2018-11-28 SG SG11202003965VA patent/SG11202003965VA/en unknown
- 2018-11-28 CN CN201880077653.6A patent/CN111432831B/en active Active
- 2018-11-28 KR KR1020207017255A patent/KR102687035B1/en active Active
- 2018-11-28 CA CA3083941A patent/CA3083941A1/en active Pending
- 2018-11-28 KR KR1020247023942A patent/KR20240115352A/en active Pending
- 2018-11-28 AU AU2018378078A patent/AU2018378078B2/en active Active
- 2018-11-28 KR KR1020247008135A patent/KR102684426B1/en active Active
-
2020
- 2020-05-21 IL IL274844A patent/IL274844A/en unknown
- 2020-06-05 ZA ZA2020/03386A patent/ZA202003386B/en unknown
-
2024
- 2024-08-29 AU AU2024216451A patent/AU2024216451A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021507690A (en) | 2021-02-25 |
| KR102684426B1 (en) | 2024-07-11 |
| JP7250790B2 (en) | 2023-04-03 |
| WO2019112854A1 (en) | 2019-06-13 |
| CN111432831A (en) | 2020-07-17 |
| CN118515780A (en) | 2024-08-20 |
| SG11202003965VA (en) | 2020-06-29 |
| BR112020011343A2 (en) | 2020-11-17 |
| KR20200097275A (en) | 2020-08-18 |
| MX2020005208A (en) | 2020-08-20 |
| KR102687035B1 (en) | 2024-07-22 |
| AU2018378078A1 (en) | 2020-06-18 |
| EP3720470A4 (en) | 2021-09-15 |
| ZA202003386B (en) | 2025-04-30 |
| KR20240115352A (en) | 2024-07-25 |
| CN111432831B (en) | 2024-08-16 |
| EP3720470A1 (en) | 2020-10-14 |
| CA3083941A1 (en) | 2019-06-13 |
| AU2018378078B2 (en) | 2024-07-25 |
| KR20240039201A (en) | 2024-03-26 |
| AU2024216451A1 (en) | 2024-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274844A (en) | Il-2 muteins and uses thereof | |
| ZA202002184B (en) | Adenovirus and uses thereof | |
| ZA202002191B (en) | Adenovirus and uses thereof | |
| IL293377B1 (en) | Hsd17b13 variants and uses thereof | |
| IL271275A (en) | Compositions comprising curons and uses thereof | |
| PL3405222T3 (en) | Novel polypeptides and medical uses thereof | |
| PT3638251T (en) | Bisphosphocin gel formulations and uses thereof | |
| IL274220A (en) | Adenovirus and uses thereof | |
| IL269836B (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| IL287503A (en) | Thiosemicarbazates and uses thereof | |
| SG11202008543RA (en) | Pyrrolidineamide derivatives and uses thereof | |
| GB202004930D0 (en) | Composition and uses thereof | |
| ZA202005144B (en) | Parenteral formulations and uses thereof | |
| SG11202004270UA (en) | Unit operation and use thereof | |
| IL275211A (en) | Fast and partition-resilient blockchains | |
| IL273671A (en) | Cornulin (crnn) variants and uses thereof | |
| IL260654B (en) | Benzenesulfonyl-asymmetric ureas and medical uses thereof | |
| IL280369A (en) | New myokines and uses thereof | |
| IL269843B (en) | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof | |
| IL261670B (en) | Magnesium-containing formulation and uses thereof | |
| GB201812952D0 (en) | Compositions and uses thereof | |
| HK40039617A (en) | Il-2 muteins and uses thereof | |
| GB201816605D0 (en) | New formulations and uses thereof | |
| GB201815546D0 (en) | Composition and uses thereof | |
| GB201716745D0 (en) | New formulations and uses thereof |